111 results about "Predictive biomarker" patented technology

The invention relates to the analysis and identification of genes that are modulated in transplant rejection. This alteration of gene expression provides a molecular signature to accurately detect transplant rejection.

The use of various biomarkers to assess a subject's suitability for treatment with a EGFR/ErbB2 kinase inhibitor for a solid tumor are described. The biomarkers include TGFalpha, pS6, IGF-1R and levels of apoptosis occurring in tumor tissue.

The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.

Systems and methods for selecting therapeutic agents for cancers using next generation sequencing, automated dissection, and/or automated slide stainers are disclosed. Non-responsive regions of a tumor sample having a heterogenous staining pattern for a predictive biomarker are excised using an automated dissection tool. Mutations linked to additional predictive biomarkers are identified in the excised portion of the sample by next generation sequencing. The relevance of the additional predictive biomarker(s) is confirmed by histochemical staining. Therapeutic courses may then be selected on the basis of the staining patterns of the predictive biomarkers.

Methods of-identifying a basal or luminal phenotype of a cell, comprising detecting expression of one or more of a set of predictive biomarker genes or proteins that identify the cell as having a basal or luminal cancer subtype and compositions for treating identified basal or luminal cancers.

The invention provides methods and compositions for treating various degenerative diseases (e.g., AMD) with a factor D inhibitor (e.g., anti-factor D antibody or antigen-binding fragment thereof). Also provided are methods of selecting or identifying patients for treatment with a factor D inhibitor. Methods include the use of prognostic and/or predictive biomarkers.

The current disclosure describes methods for identifying subjects that would benefit from treatment with a chemotherapeutic agent. The disclosure is based in part on the observation that miR-129 expression levels are reduced in colorectal cancer. Accordingly, the current disclosure provides therapeutic compositions and methods for altering the expression of a miR-129 effector. Described herein are methods for characterizing the stage of colorectal cancer in a subject, based on the levels of miR-129 expression. The disclosure also identifies miR-129 as a predictive biomarker for cancer diagnosis and the subsequent treatment with directed therapeutic agents including but not limited to miR-129 nucleic acid molecules and/or a chemotherapeutic agent. The current disclosure also identifies novel therapeutic agents that modulate the level of BCL2, TS and/or E2F3 expression, as well as sensitize a subject to treatment with a chemotherapeutic agent.

The present invention provides methods for treating metastatic cancer comprising identifying subjects who will respond favorably to anti-VEGF therapy. According to certain aspects of the invention, subjects are identified based on their expression level of one or more predictive biomarkers. Favorable response to anti-VEGF therapy is indicated by high expression levels of certain biomarkers or by low expression levels of certain biomarkers. An exemplary predictive biomarker is VEGF-A. Also disclosed herein are prognostic biomarkers useful for identifying cancer-bearing subjects who are expected to have better relative survival outcomes.

Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irAE), or combination thereof for a CTLA-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma.

The invention relates to identification of predictive biomarkers associated with Wnt pathway inhibitors. According to the invention, biomarkers are provided for identifying tumors likely to respond to treatment with Wnt pathway inhibitors. Also provided are methods for identifying tumors and/or patients that are likely to be responsive or non-responsive to treatment with a Wnt pathway inhibitor. Methods for treating a patient with cancer are provided, wherein the cancer is predicted to respond to a Wnt pathway inhibitor.

The invention relates to a predictive biomarker PD-L2 targeted polypeptide for tumor immunotherapy and an application of the predictive biomarker PD-L2 targeted polypeptide. The general formula of thepolypeptide is: HX1RX2X3X4X5RIRN. The invention also relates to a DNA fragment encoding the polypeptide, an expression vector expressing the polypeptide, a host cell and a bivalent, a multivalent orpharmaceutical composition formed from the polypeptide. The polypeptide can be used for detecting the expression of PD-L2 in tumor cells and immune cells, can be taken as a detection index for predicting the clinical efficacy of anti-PD-L1/PD-L2-PD-1 therapy and can specifically distinguish PD-L1 and PD-L2 protein with high homology, thereby having great clinical value and significance for optimization of therapeutic schedules and curative effect monitoring of individual patients.

Methods and compositions are disclosed for predicting and treating the clinical benefit to a human renal cell carcinoma patient prior to their treatment with a VEGFR inhibitor and an Ang2 inhibitor.

The invention discloses a predictive biomarker for human colorectal cancer or human colorectal cancer metastasis. The predictive biomarker comprises Ube2v1 protein. Based on the constructed colorectal cell strain with Ube2v1 over-expressed stably, the naked mouse experimental result shows that Ube2v1 can promote the growth and metastasis of tumor. Ube2v1 without functions is bonded to Ube2N for degrading histone deacetylase Sirt1, so that the deacetylation effect of Sirt1 for the H4K16 site of the histone is weakened, and the metastasis of colorectal cancer is promoted. The NSC697923 compound is added in the colorectal cancer cells, and the degradation effect of Ube2v1 for the histone deacetylase Sirt1 is obviously weakened. The result shows that Ube2v1 can be taken as the marker for the generation and metastasis of colorectal cancer, and in addition, NSC697923 can be used for preparing medicines for resisting colorectal cancer metastasis, thus having a significant clinical application value.

Predictive biomarkers identify those patients suffering from immunoglobulin positive (Ig⁺) B lineage malignancies that are responsive to active immunotherapy, where the active immunotherapy comprises vaccination with a tumor-specific idiotype-immunogen. It is shown herein that patient responsiveness to the idiotype-immunogen is dependent upon the sequence of the immunogen, where an immunogen having a low number of tyrosine residues in the CDR1 (herein termed CDR1-Y¹⁰) regions of one or both of the immunogen heavy and light chains is predictive of a positive anti-tumor response, while a high number of CDR1 tyrosine residues (herein termed CDR1-Y^hi) is predictive of a low anti tumor response.

Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.

A set of biomarkers have been identified that allows one to predict subjects who will respond to an exercise regime in term of cardiorespiratory fitness as assessed by maximal oxygen uptake. These predictions may be used, for example, to predict risk of cardiovascular disease, to design a more effective program for cardiac rehabilitation, to predict capacity for athletic performance or physically demanding occupation, and to predict ability to maintain functional capacity with aging using exercise.

Provided herein are methods of diagnosing and/or treating malignant or pre-malignant conditions in a subject. Overexpression of copy number variant-dependent genes, e.g., genes encoding a cell surface receptor, resulting from copy number changes compared to control is diagnostic of the condition, such as multiple myeloma or monoclonal gammopathy of undetermined significance. Also provided are methods for treating malignant conditions, such as multiple myeloma or a hyperdiploid subtype, with therapeutic agents, with or without other anti-cancer drugs, to downrregulate the overexpressed CNV genes and/or up-regulate the underexpressed genes. Furthermore, methods for lowering drug resistance in multiple myeloma cells via inhibition of platelet activation or thrombin release and for increasing survivability of a multiple myeloma subject via lithibition of PSMD4 gene to increase b-catenin protein expression are provided.